KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) EBITDA (2016 - 2025)

Globus Medical (GMED) has disclosed EBITDA for 15 consecutive years, with $145.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 445.02% year-over-year to $145.0 million, compared with a TTM value of $560.1 million through Dec 2025, up 426.81%, and an annual FY2025 reading of $560.1 million, up 426.81% over the prior year.
  • EBITDA was $145.0 million for Q4 2025 at Globus Medical, up from $119.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $215.3 million in Q2 2025 and bottomed at -$8.0 million in Q1 2024.
  • Average EBITDA over 5 years is $55.7 million, with a median of $43.8 million recorded in 2021.
  • Peak annual rise in EBITDA hit 4168.17% in 2024, while the deepest fall reached 114.67% in 2024.
  • Year by year, EBITDA stood at $11.4 million in 2021, then surged by 406.33% to $57.7 million in 2022, then plummeted by 59.11% to $23.6 million in 2023, then increased by 12.85% to $26.6 million in 2024, then skyrocketed by 445.02% to $145.0 million in 2025.
  • Business Quant data shows EBITDA for GMED at $145.0 million in Q4 2025, $119.7 million in Q3 2025, and $215.3 million in Q2 2025.